Meningitis is an infection, either viral or bacterial, that occurs around the brain and spinal cord. The bacterial form of this disease can have very severe consequences. According to PATH, 10 percent of victims die even with antibiotic treatment — 80 percent without any treatment — and survivors can still suffer from hearing loss or paralysis. Thankfully, a new meningitis vaccine offers hope despite these daunting statistics.
Sudan is one of 26 countries in Africa located in the “meningitis belt,” an area with a total population of about 450 million that has been deeply affected by meningitis over the past century. Epidemics arose about once every eight to 12 years according to PATH, and in 1996 twenty-five thousand people were killed in the largest meningitis epidemic.
Addressing meningitis in Africa is difficult because although meningitis A is one of the main causes of epidemics in Africa, most industrialized countries have meningitis C posing the largest problem. As a result, vaccine manufacturers focus on designing vaccines for industrialized countries to net more profit, and unfortunately, African countries then fail to receive the types of vaccines they need to combat meningitis A.
MVP to the Rescue
The creation of the Meningitis Vaccine Project (MVP) via a collaboration between the WHO and PATH in 2001 did much to help the situation. MVP was able to create a meningitis A vaccine, trademarked as MenAfriVac, that could also be cheaply administered for less than 50 cents for one dose.
MVP then introduced the vaccine in mass vaccination campaigns, and as a result 235 million people gained immunity. Amazingly, only 80 cases of meningitis A were recorded in 2015 — a huge improvement compared to the 250,000 reported cases from the 1996 epidemic.
Continuing the Success
So why then is Sudan incorporating the vaccine into its routine immunization program important if so much progress has been made in reducing meningitis outbreaks? Despite the success of the current round of immunizations, if the vaccines are not continually administered in the future, epidemics could begin again in as early as fifteen years.
The fact that the meningitis A vaccine is now part of Sudan’s routine immunization program means that at birth children will automatically receive the vaccine. As long as this program remains in effect, Sudan will likely not have to worry about meningitis. This year, 720,000 Sudanese children less than one year of age are expected to receive the vaccine.
Additionally, another vaccination campaign targeting children between one and five years old will go into effect this September. These children might have missed out on the Sudanese vaccination campaign that took place in 2012 and 2013, so the additional vaccinations provide another precaution against an outbreak.
Other countries should follow Sudan in adopting the meningitis vaccine into routine immunization programs. That way, these countries will be able to suppress meningitis on their own even without vaccination campaigns, and help hundreds to combat the deadly infection.
– Edmond Kim